Download
Company intelligence · Prepared from public filings
Artios Pharma Limited
ACTIVENo. 09931309Incorporated 29 Dec 2015CambridgeDNA damage response drug discovery
Register data as of 27 Aug 2026
52 filings read · view all sources ↓
Watch this company52 filings read · view all sources ↓
Raised, filed rounds
£7.2m
Priced rounds
2
Peak step-up
8.0x
Peak implied valuation
£103.7m
Last allotment
Jan 2017
Exhibit 1
Implied valuation at each priced allotment, 2016 to 2017
Implied post-money, GBP · price per share beneath each point · from SH01 filings
Source: Companies House, forms SH01 filed by Artios Pharma Limited; Tero analysis. Each point is one filed allotment; click any point to open the underlying filing.
Exhibit 2
Funding rounds, as filed
| Allotted | Share class | Price / share | Raised | Implied post-money | Step vs prior | Source |
|---|---|---|---|---|---|---|
| 11 Jan 2017 | Ordinary | £5.97 | £3.6m | £103.7m | ▲ 8.0x | SH01 ↗ |
| 20 Sept 2016 | Ordinary, Series A | £0.75 | £3.6m | £12.6m | first | SH01 ↗ |
| Total, 2 priced rounds | £7.2m | |||||
Source: Companies House filing history, company 09931309. Every row links to the filed document it was read from. Prices and share counts as filed; implied post-money is price per share times shares in issue after the allotment.
Methodology
Notes. Raised is the sum of shares allotted times price per share across priced allotments filed on form SH01. Peak step-up is the highest price per share divided by the first priced round. Implied post-money is price per share times shares in issue after the allotment: an approximation that ignores class rights and unexercised options. Allotments classified as option-scheme or nominal issues are excluded from the trajectory.Primary documents
Every figure on this page is read from a document filed at Companies House and links to it. The full record is public: filing history of Artios Pharma Limited at Companies House ↗. Tero retains an archived copy of each parsed filing. Information, not investment advice.